Icon Plc (NASDAQ:ICLR) Receives $205.31 Consensus Target Price from Analysts

by · The Cerbat Gem

Shares of Icon Plc (NASDAQ:ICLR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty-one analysts that are covering the firm, MarketBeat reports. Eleven research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $205.3125.

A number of equities research analysts have weighed in on the company. TD Cowen decreased their target price on Icon from $183.00 to $172.00 and set a “hold” rating for the company in a research report on Friday, October 24th. Weiss Ratings restated a “hold (c)” rating on shares of Icon in a research note on Monday. Cowen reaffirmed a “hold” rating on shares of Icon in a research note on Friday, October 24th. Rothschild Redb upgraded shares of Icon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Finally, UBS Group set a $220.00 price target on shares of Icon in a report on Friday, October 24th.

Check Out Our Latest Research Report on ICLR

Icon Stock Performance

Icon stock opened at $183.64 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market capitalization of $14.83 billion, a PE ratio of 24.85, a P/E/G ratio of 3.39 and a beta of 1.25. The company has a 50 day moving average price of $175.50 and a 200-day moving average price of $169.31. Icon has a fifty-two week low of $125.10 and a fifty-two week high of $228.29.

Institutional Trading of Icon

A number of hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA boosted its position in Icon by 200.0% during the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 94 shares in the last quarter. SVB Wealth LLC purchased a new stake in shares of Icon during the 1st quarter worth $28,000. Ameriflex Group Inc. purchased a new stake in shares of Icon during the 3rd quarter worth $33,000. Ameritas Advisory Services LLC bought a new stake in Icon during the second quarter valued at about $48,000. Finally, LRI Investments LLC purchased a new position in Icon in the second quarter valued at about $49,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Company Profile

(Get Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.

Further Reading